Salivary free concentrations of anti-epileptic drugs

An evaluation in a routine clinical setting

Mohammed Al Za'abi, Dirik Deleu, Chris Batchelor

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objective: This study was aimed at correlating the salivary and serum free concentrations of anti-epileptic drugs (carbamazepine, phenytoin and sodium valproate) in a population of neurological patients in a routine clinical setting. Method: Twenty-seven paired serum/saliva specimens from 22 patients : 10 for carbamazepine, 8 for phenytoin and 9 for sodium valproate were obtained to study these correlations. Salivary and serum free concentrations of anti-epileptic drugs, anti-epileptic drug dosing history, and associated information were collected prospectively. The salivary and serum free concentrations of the anti-epileptic drugs were simultaneously quantified using fluorescence polarization immunoassay (TDx analyzer). Results: For both carbamazepine and phenytoin there was a strong correlation between the salivary and serum free concentrations, 0.99 and 0.98, respectively. The mean ratio of salivary to serum free carbamazepine concentration was 1.02 ± 0.11 and 0.82 ± 0.15 for phenytoin. A poor correlation between salivary and serum free concentration was observed for sodium valproate (0.70) with a mean ratio of salivary to serum free concentration of 0.48 ± 0.27. Conclusion: Monitoring of free salivary concentrations of anti-epileptic drugs, particularly phenytoin and carbamazepine proved to be a realistic alternative in this routine clinical setting.

Original languageEnglish
Pages (from-to)19-23
Number of pages5
JournalActa Neurologica Belgica
Volume103
Issue number1
Publication statusPublished - 2003

Fingerprint

Drug Evaluation
Carbamazepine
Phenytoin
Serum
Valproic Acid
Pharmaceutical Preparations
Fluorescence Polarization Immunoassay
Saliva
History

Keywords

  • Adults
  • Carbamazepine
  • Epilepsy
  • Phenytoin
  • Saliva
  • Serum
  • Sodium valproate
  • Unbound

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Salivary free concentrations of anti-epileptic drugs : An evaluation in a routine clinical setting. / Al Za'abi, Mohammed; Deleu, Dirik; Batchelor, Chris.

In: Acta Neurologica Belgica, Vol. 103, No. 1, 2003, p. 19-23.

Research output: Contribution to journalArticle

@article{bf6f1d96597c493eba6cf96601a56b19,
title = "Salivary free concentrations of anti-epileptic drugs: An evaluation in a routine clinical setting",
abstract = "Objective: This study was aimed at correlating the salivary and serum free concentrations of anti-epileptic drugs (carbamazepine, phenytoin and sodium valproate) in a population of neurological patients in a routine clinical setting. Method: Twenty-seven paired serum/saliva specimens from 22 patients : 10 for carbamazepine, 8 for phenytoin and 9 for sodium valproate were obtained to study these correlations. Salivary and serum free concentrations of anti-epileptic drugs, anti-epileptic drug dosing history, and associated information were collected prospectively. The salivary and serum free concentrations of the anti-epileptic drugs were simultaneously quantified using fluorescence polarization immunoassay (TDx analyzer). Results: For both carbamazepine and phenytoin there was a strong correlation between the salivary and serum free concentrations, 0.99 and 0.98, respectively. The mean ratio of salivary to serum free carbamazepine concentration was 1.02 ± 0.11 and 0.82 ± 0.15 for phenytoin. A poor correlation between salivary and serum free concentration was observed for sodium valproate (0.70) with a mean ratio of salivary to serum free concentration of 0.48 ± 0.27. Conclusion: Monitoring of free salivary concentrations of anti-epileptic drugs, particularly phenytoin and carbamazepine proved to be a realistic alternative in this routine clinical setting.",
keywords = "Adults, Carbamazepine, Epilepsy, Phenytoin, Saliva, Serum, Sodium valproate, Unbound",
author = "{Al Za'abi}, Mohammed and Dirik Deleu and Chris Batchelor",
year = "2003",
language = "English",
volume = "103",
pages = "19--23",
journal = "Acta Neurologica Belgica",
issn = "0300-9108",
publisher = "Springer-Verlag Italia",
number = "1",

}

TY - JOUR

T1 - Salivary free concentrations of anti-epileptic drugs

T2 - An evaluation in a routine clinical setting

AU - Al Za'abi, Mohammed

AU - Deleu, Dirik

AU - Batchelor, Chris

PY - 2003

Y1 - 2003

N2 - Objective: This study was aimed at correlating the salivary and serum free concentrations of anti-epileptic drugs (carbamazepine, phenytoin and sodium valproate) in a population of neurological patients in a routine clinical setting. Method: Twenty-seven paired serum/saliva specimens from 22 patients : 10 for carbamazepine, 8 for phenytoin and 9 for sodium valproate were obtained to study these correlations. Salivary and serum free concentrations of anti-epileptic drugs, anti-epileptic drug dosing history, and associated information were collected prospectively. The salivary and serum free concentrations of the anti-epileptic drugs were simultaneously quantified using fluorescence polarization immunoassay (TDx analyzer). Results: For both carbamazepine and phenytoin there was a strong correlation between the salivary and serum free concentrations, 0.99 and 0.98, respectively. The mean ratio of salivary to serum free carbamazepine concentration was 1.02 ± 0.11 and 0.82 ± 0.15 for phenytoin. A poor correlation between salivary and serum free concentration was observed for sodium valproate (0.70) with a mean ratio of salivary to serum free concentration of 0.48 ± 0.27. Conclusion: Monitoring of free salivary concentrations of anti-epileptic drugs, particularly phenytoin and carbamazepine proved to be a realistic alternative in this routine clinical setting.

AB - Objective: This study was aimed at correlating the salivary and serum free concentrations of anti-epileptic drugs (carbamazepine, phenytoin and sodium valproate) in a population of neurological patients in a routine clinical setting. Method: Twenty-seven paired serum/saliva specimens from 22 patients : 10 for carbamazepine, 8 for phenytoin and 9 for sodium valproate were obtained to study these correlations. Salivary and serum free concentrations of anti-epileptic drugs, anti-epileptic drug dosing history, and associated information were collected prospectively. The salivary and serum free concentrations of the anti-epileptic drugs were simultaneously quantified using fluorescence polarization immunoassay (TDx analyzer). Results: For both carbamazepine and phenytoin there was a strong correlation between the salivary and serum free concentrations, 0.99 and 0.98, respectively. The mean ratio of salivary to serum free carbamazepine concentration was 1.02 ± 0.11 and 0.82 ± 0.15 for phenytoin. A poor correlation between salivary and serum free concentration was observed for sodium valproate (0.70) with a mean ratio of salivary to serum free concentration of 0.48 ± 0.27. Conclusion: Monitoring of free salivary concentrations of anti-epileptic drugs, particularly phenytoin and carbamazepine proved to be a realistic alternative in this routine clinical setting.

KW - Adults

KW - Carbamazepine

KW - Epilepsy

KW - Phenytoin

KW - Saliva

KW - Serum

KW - Sodium valproate

KW - Unbound

UR - http://www.scopus.com/inward/record.url?scp=0037357235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037357235&partnerID=8YFLogxK

M3 - Article

VL - 103

SP - 19

EP - 23

JO - Acta Neurologica Belgica

JF - Acta Neurologica Belgica

SN - 0300-9108

IS - 1

ER -